There are numerous challenges to finding effective treatments for mental disorders. However, Blackthorn Therapeutics, a neurobehavioral health company using machine learning to create personalized medicine for mental health, is betting its technological approach to finding drugs that work will put it ahead of the competition. Lucky for them, GV and other biotech investors have shown they agree by adding another $76 million in Series B financing to the coffers.
Today, Blackthorn announced the close of its $76 million series B round from GV, Scripps Research, Johnson & Johnson Innovation and a bevy of other biotech investment firms, including Polaris Partners, Premier Partners, Vertex Ventures HC, Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, and Biomatics Capita.
Blackthorn has been heads down the last couple of years on a clinical trial for a drug that could potentially treat mood disorders. In April, the company announced positive results from its phase I trial for the drug.
The company plans to use the funding to advance its clinical-stage programs for mood disorders as well as for potential treatment of autism spectrum disorder, advancing towards clinical investigation in 2020.
Brian Chee, a managing partner at Polaris Partners, Lori Hu,
This post was originally published on this site
